# A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

> **NCT03126591** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 41 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Olaratumab
- **DRUG:** Pembrolizumab (KEYTRUDA®)

## Key facts

- **NCT ID:** NCT03126591
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-03
- **Primary completion:** 2021-05-06
- **Final completion:** 2023-02-21
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03126591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03126591, "A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03126591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*